Get the Stockscreener App
28.94
0.52%
-0.15
After Hours:
28.92
-0.02
-0.07%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $28.94, with a volume of 26.35M.
It is down -0.52% in the last 24 hours and down -0.24% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$29.09
Open:
$29.11
24h Volume:
26.35M
Relative Volume:
0.89
Market Cap:
$163.51B
Revenue:
$55.64B
Net Income/Loss:
$-2.60B
P/E Ratio:
15.81
EPS:
1.83
Net Cash Flow:
$4.81B
1W Performance:
-1.26%
1M Performance:
-0.24%
6M Performance:
+4.29%
1Y Performance:
-12.75%
1-Day Range:
$28.78
$29.19
1-Week Range:
$28.31
$29.71
52-Week Range:
$25.20
$34.11
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Health Care Up as Traders Seek Out Less Rate-Sensitive Sectors -- Health Care Roundup - Marketscreener.com
Pfizer to raise around GBP2.7 billion from Haleon stake sale - Marketscreener.com
Top 3 Discounted Value Stocks Worth Buying Now - Investing.com
Pfizer (NYSE:PFE) Trading Up 0% - MarketBeat
Bookrunner Says Haleon PLC ABB Sale Of Shares By Pfizer Inc Deal Upsized To 640MM Shares / C. USD 3.25bn - XM
Pfizer Paring Haleon Stake With 540 Million Share Sale - Yahoo Finance
Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner - AOL
Bookrunner Says Haleon Secondary ABB's Sale Of Shares By Pfizer Books Are Covered - XM
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update - MarketWatch
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering - BNN Bloomberg
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon - Marketscreener.com
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner - Yahoo Canada Finance
Proposed purchase alongside Pfizer offering - ShareCast
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Yahoo Finance
Superluminal Medicines Announces Formation of Scientific Advisory Board - The Manila Times
15 Best Dividend Stocks for Lifelong Passive Income - The Motley Fool
Creative Planning Has $43.50 Million Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer's SWOT analysis: stock outlook amid transformation and pipeline growth - Investing.com India
Pipeline Moves: Pfizer scores in Phase II cancer cachexia trial - Clinical Trials Arena
Pfizer Inc. (PFE) Acquires Seagen for $43 Billion, Strengthening Oncology Leadership - Yahoo Finance
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks - KIRO Seattle
Pfizer pulls sickle cell drug oxbryta, raising safety concerns - BizNews
Mackenzie Financial Corp Sells 893,578 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Here is What Jim Cramer Likes Pfizer Inc. (NYSE:PFE) - Yahoo Finance
A Letter from Pfizer’s Chairman and CEO, Albert Bourla - Pfizer
Pfizer Owes Sickle Cell Patients a Better Explanation - Bloomberg
3 Surprisingly Underrated Stocks to Buy Right Now - The Motley Fool
The Manufacturers Life Insurance Company Reduces Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
PFE Stock Quote Price and Forecast - CNN
Pink Sheet Podcast: Pfizer Pulls Sickle Cell Drug, ODAC Calls Back Approved Products, New AAM CEO - Pink Sheet
Pfizer (NYSE:PFE) Trading 0.3% Higher - MarketBeat
Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat - Morningstar
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal - Seeking Alpha
FDA alerts patients about Pfizer's Oxbryta withdrawal - Reuters
Pfizer: A 6% Yielding Value Deal (NYSE:PFE) - Seeking Alpha
Why are Genentech cancer researchers worried? - STAT
Pfizer: Jefferies lowers price target - Marketscreener.com
Caxton Associates LP Invests $738,000 in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Pulls Key Sickle Cell Drug Over Safety Concerns - Finimize
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason - The Motley Fool
PFIZER INC : Jefferies gives a Buy rating - Marketscreener.com
Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited - Pink Sheet
Sickle cell mechanisms that could fill the hole left by Pfizer’s Oxbryta withdrawal - BioCentury
Pfizer (PFE) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Pfizer Inc. stock rises Thursday, still underperforms market - MarketWatch
Pfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta Pull - Bloomberg
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA - STAT
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say - Yahoo Finance
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - MSN
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - Seeking Alpha
Pfizer (NYSE:PFE) Trading Down 0.6% - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 13 '24 |
Sale |
28.66 |
5,154 |
147,714 |
8,582 |
| McDermott Michael | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
12,412 |
339,344 |
95,408 |
| SUSMAN SALLY | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
63,837 |
1,745,304 |
218,148 |
| SAHNI PAYAL | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
11,527 |
315,148 |
34,604 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
95,755 |
2,617,942 |
230,920 |
| JOHNSON RADY A | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
29,436 |
804,780 |
123,073 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 23 '24 |
Option Exercise |
27.34 |
9,752 |
266,620 |
19,228 |
| BOURLA ALBERT | Chairman & CEO |
Feb 23 '24 |
Option Exercise |
27.34 |
127,674 |
3,490,607 |
439,748 |
| BOSHOFF CHRISTOFFEL | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
9,752 |
266,620 |
148,703 |
| Gottlieb Scott | Director |
Dec 15 '23 |
Buy |
26.47 |
3,000 |
79,401 |
9,000 |
0.14%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):